Finlay J L, Geyer J R, Turski P A, Yates A J, Boyett J M, Allen J C, Packer R J
Memorial Sloan-Kettering Cancer Center, New York, NY.
J Neurooncol. 1994;21(3):255-65. doi: 10.1007/BF01063775.
This study was undertaken to evaluate the radiographic response to two cycles of chemotherapy prior to irradiation in newly diagnosed children with high-grade astrocytomas.
One hundred and thirty children less than 21 years of age with newly-diagnosed high-grade astrocytoma were treated with the 'eight-drugs-in-one-day' chemotherapy regimen as part of a phase III multi-institutional Childrens Cancer Group (CCG) trial. Computerized Tomographic (CT) or Magnetic Resonance Image (MRI) scans, obtained after two cycles of chemotherapy had been administered, were compared with post-operative scans to determine treatment response. Scans were evaluated by institutional radiologists, and were reviewed centrally by a single neuroradiologist.
Of 79 patients with evaluable post-operative residual tumor on CT or MRI scans, 26 (33%) were determined on institutional evaluation to have had an objective response. However, central review of scans documented responses on only 14/79 (18%). A significantly higher response rate on central review was observed for those children 36 months of age or less at study entry than for older children (33% v 11%; p < 0.001). However, a higher disease progression rate was also observed for those children 36 months of age or less than for older children (21% v 2.6%; p < 0.001).
In this study, the largest yet reported in newly-diagnosed children with high-grade astrocytomas, the chemotherapy regimen has activity in younger children. The differences in response rates reported by institutional and central review highlight the difficulties inherent in assessing response to brain tumor therapy. However, the study does demonstrate the consistent ability of radiologists to identify disease progression within the institutional and central reviews.
本研究旨在评估新诊断的高级别星形细胞瘤患儿在放疗前接受两个周期化疗后的影像学反应。
130名年龄小于21岁的新诊断高级别星形细胞瘤患儿接受了“一日八药”化疗方案,这是一项III期多机构儿童癌症组(CCG)试验的一部分。在给予两个周期化疗后进行的计算机断层扫描(CT)或磁共振成像(MRI)扫描与术后扫描进行比较,以确定治疗反应。扫描由机构放射科医生进行评估,并由一名神经放射科医生进行集中审查。
在79名CT或MRI扫描显示有可评估术后残留肿瘤的患者中,机构评估确定26名(33%)有客观反应。然而,扫描的集中审查仅记录了14/79(18%)有反应。研究入组时年龄在36个月及以下的儿童在集中审查中的反应率显著高于年龄较大的儿童(33%对11%;p<0.001)。然而,年龄在36个月及以下的儿童疾病进展率也高于年龄较大的儿童(21%对2.6%;p<0.001)。
在这项新诊断的高级别星形细胞瘤患儿的研究中,这是迄今为止报告的最大规模研究,化疗方案对年幼儿童有活性。机构审查和集中审查报告的反应率差异突出了评估脑肿瘤治疗反应所固有的困难。然而,该研究确实证明了放射科医生在机构审查和集中审查中识别疾病进展的一致能力。